Kiyaros 20 Tablet contains Rosuvastatin 20mg, a potent HMG-CoA reductase inhibitor used primarily to manage hypercholesterolemia and reduce cardiovascular risk. Rosuvastatin works by selectively inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the biosynthesis of cholesterol in the liver. This results in decreased levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides, while modestly increasing high-density lipoprotein cholesterol (HDL-C). Kiyaros 20 is indicated for patients with primary hyperlipidemia, mixed dyslipidemia, and familial hypercholesterolemia, as well as for the prevention of atherosclerotic cardiovascular disease in individuals at high risk. The medication is typically administered once daily, with or without food, and dosage adjustments should be based on therapeutic response and patient tolerance. Common adverse effects may include headache, myalgia, abdominal pain, and nausea, while rare but serious side effects include myopathy and rhabdomyolysis. Liver function tests and lipid profiles should be monitored periodically during treatment. Kiyaros 20 should be used cautiously in patients with hepatic impairment or a history of muscle disorders, and it is contraindicated during pregnancy and lactation. Patient adherence to lifestyle modifications alongside pharmacotherapy is essential for optimal outcomes.